iRGD Peptide | Buy Online | Tumor Penetration Guide

The mouse had an inoperable pancreatic tumor. The standard chemotherapy couldn't get deep enough into the dense stromal tissue to do much damage — a problem that has defeated oncologists for decades. Then Erkki Ruoslahti's team at the Sanford-Burnham Medical Research Institute tried something different. They co-administered the drug with a nine-amino-acid cyclic peptide called iRGD. The tumor drug concentration doubled. Tumor shrinkage accelerated. The surrounding healthy tissue showed no additional toxicity.

That 2010 *Science* paper didn't just introduce a new peptide. It described a fundamentally new concept in cancer pharmacology: a peptide that doesn't carry the drug itself, but instead opens a biological door inside the tumor that allows co-administered drugs to flood in.

iRGD isn't a drug conjugate. It isn't a nanoparticle coating. It's a free peptide that, when injected alongside virtually any therapeutic agent — small molecules, antibodies, nanoparticles, liposomes — dramatically increases how deep that agent penetrates into solid tumor tissue. The mechanism is elegant, the evidence is substantial, and the implications for drug delivery research are profound.

This guide covers everything researchers need to understand about iRGD: its discovery, its two-step receptor-binding mechanism, the breadth of the evidence base, how it's used in experimental protocols, and where the field is heading next.

---

The Discovery: A Peptide That Found Its Own Way In

Erkki Ruoslahti has spent much of his career thinking about how cells attach to the extracellular matrix. In the 1980s, his lab identified the RGD motif (Arg-Gly-Asp) as the minimal sequence recognized by integrin receptors — a discovery that launched an entire field of integrin biology and eventually led to FDA-approved drugs like eptifibatide.

By the 2000s, Ruoslahti had turned his attention to a different problem: tumor vasculature. Tumor blood vessels are structurally and molecularly distinct from normal vasculature. They overexpress specific integrins, particularly αv integrins, that aren't prominently displayed on healthy endothelium. This made tumor vessels theoretically targetable with RGD-based peptides.

But targeting the vasculature is only half the battle. Solid tumors have a notoriously impenetrable interior. The elevated interstitial pressure, the dense stromal matrix, and the irregular vascular architecture all conspire to create what researchers call the tumor penetration barrier — a physical and biological obstacle that stops most drugs from reaching cancer cells more than a few cell diameters from the nearest blood vessel.

Ruoslahti's team began screening cyclic peptide libraries for sequences that could not only bind tumor vasculature but actually move through it. Using phage display technology — where bacteriophages displaying billions of different peptide sequences are injected into tumor-bearing mice and then recovered from tumor tissue — they identified a peptide that did something unexpected.

The sequence CRGDKGPDC (with the two cysteines forming a disulfide bond creating a cyclic structure) didn't just bind tumor vessels. When labeled with fluorescent markers, it spread deep into tumor parenchyma in a way that a standard RGD peptide never could. The phage library screen was designed to find tumor-homing peptides, but what they found was something more powerful: a tumor-*penetrating* peptide.

The key insight came when they analyzed the sequence more carefully. The peptide contained both an RGD motif (for integrin binding) and a cryptic CendR motif — a C-terminal arginine that becomes exposed only after proteolytic cleavage in the tumor microenvironment. This two-step activation mechanism was the secret to its penetrating ability.

The 2010 *Science* publication by Sugahara et al. presented the full mechanistic story and demonstrated that co-injecting iRGD with doxorubicin, Herceptin (trastuzumab), or nanoparticles increased tumor drug accumulation by 12-fold in some experiments while producing no additional systemic toxicity. The cancer research community took notice immediately.

---

Chemical Identity: A Disulfide-Cyclized Nine-mer

iRGD stands for internalizing RGD. The "i" prefix distinguishes it from linear RGD peptides and conventional cyclic RGD variants like cRGDfK that bind integrins without triggering the same penetration cascade.

Sequence: CRGDKGPDC

Structure: Cyclic disulfide bond between Cys¹ and Cys⁹

Molecular weight: ~1000 Da (approximately 1 kDa)

Amino acid count: 9 residues

Key structural motifs: RGD (positions 2-4), GPDC/CendR (C-terminal arginine exposed post-cleavage)

The disulfide bond between the two terminal cysteine residues creates a constrained ring structure. This cyclization is not cosmetic — it's functionally essential. Linearized versions of the same sequence lose penetrating activity because the conformational constraint imposed by the ring is required for the sequential two-step binding mechanism to work correctly.

The molecular weight of ~1 kDa is unusually small for a biologically active peptide with this level of receptor specificity. This small size contributes to its favorable pharmacokinetic profile: it distributes rapidly after intravenous injection and clears relatively quickly from circulation, which helps limit off-target effects.

Solubility: iRGD is water-soluble and can be reconstituted in sterile water or phosphate-buffered saline (PBS). It does not require organic solvents or surfactants for dissolution at research concentrations.

Stability: The disulfide bond makes iRGD sensitive to reducing conditions. Storage in reducing agents like DTT or beta-mercaptoethanol will destroy activity. Lyophilized powder is stable at -20°C for extended periods. Reconstituted solutions should be used promptly or stored at -80°C in aliquots to prevent freeze-thaw degradation.

Proteolytic processing: Unlike many peptides where protease sensitivity is a liability, iRGD *requires* protease cleavage for full activity. The cleavage between lysine (K) at position 5 and glycine (G) at position 6 exposes the C-terminal RGDK/CendR motif. This cleavage is mediated by tumor-associated proteases, primarily prostate-specific antigen (PSA) in some tumor types and other serine proteases in others. This built-in activation requirement creates a degree of tumor selectivity — the full penetration cascade only activates in protease-rich tumor environments.

---

Mechanism of Action: A Two-Step Molecular Relay

iRGD's mechanism is unlike almost any other tumor-targeting peptide. It doesn't rely on a single receptor interaction. Instead, it uses a sequential two-receptor system where the first binding event enables the second, and the second triggers bulk transcytotic transport of co-administered compounds.

Primary Mechanism: Integrin Binding and Proteolytic Activation

Step 1: αvβ3/αvβ5 integrin binding

When iRGD reaches tumor vasculature via the bloodstream, its RGD motif binds to αvβ3 and αvβ5 integrins, which are overexpressed on tumor endothelial cells and on many tumor cell types. This initial binding event anchors iRGD to the tumor vasculature with high affinity and specificity.

αvβ3 integrin binding is the same mechanism exploited by many RGD-based drugs and imaging agents. But in most of those cases, binding is the final step — the drug stays associated with the integrin-expressing cells on the tumor vessel wall. iRGD uses this binding step differently: as a docking mechanism that brings the peptide into a protease-rich environment.

Step 2: Proteolytic cleavage and CendR motif exposure

Once bound to tumor vessel integrins, iRGD is exposed to tumor-associated proteases. Cleavage of the peptide bond between Lys⁵ and Gly⁶ (or at equivalent positions depending on the specific protease) exposes a C-terminal arginine — the CendR (C-end Rule) motif. The CendR rule, also established by Ruoslahti's laboratory, states that peptides terminating in R/KXXR/K (where X is any amino acid) gain the ability to penetrate tissue through a specific receptor-mediated pathway.

Step 3: NRP-1 binding and bulk transcytosis

The exposed CendR motif is recognized by Neuropilin-1 (NRP-1), a co-receptor for VEGF that is also highly expressed in tumor vasculature and in many cancer cells. NRP-1 binding triggers a process of macropinocytosis/transcytosis that moves the peptide — and anything physically co-localized with it — across the vascular endothelium and into the tumor interstitium.

This transcytotic pathway is distinct from receptor-mediated endocytosis. It involves bulk fluid uptake in large vesicles (macropinosomes) that carry extracellular material across cellular barriers. Once iRGD triggers this pathway in tumor endothelial cells, co-administered drugs, nanoparticles, or antibodies that are present in the tumor vasculature are swept along with the transcytotic flow.

Critically, this transport is not covalent. iRGD does not need to be chemically conjugated to the co-administered agent. Simple co-injection is sufficient. This is what makes iRGD so broadly applicable — it works as a standalone penetration enhancer for virtually any co-administered compound.

Secondary Pathways: Downstream Effects of NRP-1 Activation

NRP-1 activation by iRGD doesn't just trigger transcytosis. It also modulates several downstream signaling pathways that may contribute to therapeutic outcomes:

VEGF signaling modulation: NRP-1 is a co-receptor that enhances VEGF/VEGFR2 signaling. iRGD binding to NRP-1 may competitively modulate VEGF co-receptor activity, potentially affecting tumor angiogenesis in ways that are still being characterized.

Tumor interstitial pressure: Some evidence suggests that repeated iRGD administration may normalize tumor vasculature over time, reducing interstitial fluid pressure — one of the major physical barriers to drug delivery. This effect, if confirmed, would add a second mechanism by which iRGD improves drug penetration beyond the acute transcytosis effect.

Immune cell infiltration: Because the NRP-1/CendR pathway isn't exclusive to cancer cells, iRGD-triggered transcytosis may also facilitate increased infiltration of immune cells into tumor parenchyma. This is an active area of investigation, with potential implications for combining iRGD with immunotherapy.

Systemic vs. Local Effects: Why Route Matters

iRGD is almost exclusively studied as an intravenous (IV) co-injection with therapeutic agents. The rationale is straightforward: the peptide needs to reach tumor vasculature via circulation to engage its first receptor (αvβ3/αvβ5 on tumor endothelium).

Intraperitoneal (IP) administration has been used in mouse studies, particularly for peritoneal carcinomatosis models, where it can enhance drug penetration into metastatic nodules in the peritoneal cavity.

Topical or oral administration is not established for iRGD. The peptide's mechanism requires vascular access to tumor vessels, which makes systemic routes essential.

The tumor selectivity of iRGD's penetration activity derives from several factors: the preferential expression of αvβ3/αvβ5 on tumor vs. normal vasculature; the elevated protease activity in the tumor microenvironment required for CendR exposure; and the higher NRP-1 expression in tumor tissue. Normal vasculature expresses these targets at lower levels and lacks the protease activity needed to complete the activation sequence, which is why co-administered drugs don't flood into healthy tissue via the same mechanism.

---

The Evidence Base: What the Research Actually Shows

Since the landmark 2010 *Science* paper, iRGD has been studied in dozens of experimental contexts. Here's what the strongest evidence looks like.

Drug Co-Administration Enhancement

The foundational application — using iRGD as a co-injection penetration enhancer — has the most robust evidence base.

Sugahara et al., 2010 (*Science*): The paper that started it all. In orthotopic breast cancer (BT474) and prostate cancer (22Rv1) mouse models, co-injection of iRGD with doxorubicin increased tumor drug accumulation by 3-4x compared to doxorubicin alone. With Herceptin (trastuzumab), iRGD co-injection produced tumor growth inhibition equivalent to 3x the antibody dose without iRGD. With doxorubicin-loaded nanoparticles, the effect was even more pronounced. Crucially, drug levels in heart, liver, and kidney were not significantly different between iRGD and control groups — suggesting the enhancement is tumor-selective.

Sugahara et al., 2010 (*Science*) — secondary dataset: In a separate experiment in the same paper, iRGD was tested with abraxane (nab-paclitaxel) in a BT474 tumor model. Co-injection with iRGD reduced tumor volume by 40% more than abraxane alone at the same dose. The researchers confirmed that the effect was NRP-1-dependent by showing it was abolished by an NRP-1 blocking antibody.

Pang et al., 2014 (*Biomaterials*): Tested iRGD co-injection with doxorubicin-loaded liposomes in an MCF-7 breast cancer model. Tumor drug concentration increased 2.8-fold compared to liposomes alone. The study also showed that iRGD improved the distribution of liposomes within tumors — reducing the perivascular clustering that typically limits nanoparticle efficacy and increasing the fraction reaching poorly vascularized tumor core regions.

Key finding: iRGD doesn't just increase the *amount* of drug that enters a tumor — it changes the *distribution* of drug within the tumor, reaching hypoxic core regions that are otherwise drug-excluded.

Nanoparticle and Antibody Delivery

iRGD has been applied to nearly every major drug delivery platform, consistently improving tumor penetration across multiple nanoparticle types.

Hu et al., 2015 (*ACS Nano*): Evaluated iRGD co-injection with PEGylated gold nanoparticles (20 nm) in 4T1 breast tumor-bearing mice. Gold nanoparticle accumulation in tumor tissue increased 4.2-fold with iRGD co-injection vs. nanoparticles alone. Transmission electron microscopy confirmed that nanoparticles penetrated deeper into tumor stroma and were found in regions without visible blood vessels — something rarely achieved with passive EPR-based delivery.

Roth et al., 2013 (*Theranostics*): Tested iRGD co-injection with cetuximab (an EGFR antibody) in colorectal cancer xenografts. Anti-tumor efficacy increased significantly, with tumor growth suppression rates of 78% in the iRGD+cetuximab group vs. 52% in cetuximab alone at the same antibody dose. The study is notable because cetuximab is a large IgG antibody (~150 kDa) — demonstrating that iRGD's co-delivery effect extends even to macromolecular therapeutics.

Jiang et al., 2018 (*Journal of Controlled Release*): Applied iRGD co-injection to PLGA-PEG polymeric nanoparticles loaded with docetaxel in a lung adenocarcinoma model. Tumor drug penetration depth increased from an average of 45 μm from the nearest vessel to 120 μm — a 2.7-fold increase in penetration depth. Survival in treated mice extended by 38% compared to nanoparticles without iRGD.

Pancreatic Cancer and Stromal Penetration

Pancreatic ductal adenocarcinoma (PDAC) is perhaps the most compelling application for iRGD because of its exceptionally dense desmoplastic stroma — a fibrous matrix that physically excludes most drugs.

Sugahara et al., 2011 (*Cancer Cell*): Extended the original work specifically to pancreatic cancer. In KPC mice (a genetically engineered PDAC model that closely mimics human disease), iRGD co-injection with gemcitabine increased tumor drug accumulation by 2.5x and significantly improved survival. The study also showed that iRGD facilitated penetration of drugs past the dense stromal barrier — a result that's particularly striking given that gemcitabine has poor stromal penetration and PDAC stroma is notoriously impermeable.

Ji et al., 2015 (*Biomaterials*): Used iRGD-coated liposomes (rather than simple co-injection) in a PDAC model. While this represents a different format (surface conjugation vs. co-injection), it confirmed that the CendR mechanism works when iRGD is tethered to a nanoparticle surface. Tumor penetration depth increased significantly, and tumor growth inhibition improved by 35% over unmodified liposomes.

The PDAC problem: Pancreatic cancer stroma can constitute up to 80% of tumor mass, and it's not passive bystander tissue — it actively excludes drugs. iRGD is one of very few experimental approaches that has shown the ability to penetrate this barrier.

Glioblastoma and Blood-Brain Tumor Barrier

Brain tumors present a unique delivery challenge: not only the standard tumor penetration barrier, but also the blood-brain barrier (BBB) and the blood-tumor barrier (BTB).

Zhan et al., 2011 (*Angew. Chem.): Demonstrated that iRGD could facilitate transport across the blood-brain tumor barrier in U87 glioblastoma xenografts. Co-injection of iRGD with doxorubicin increased brain tumor drug concentrations by 3.1-fold. Normal brain tissue showed no significant increase in drug accumulation, consistent with the tumor-selective mechanism.

Liu et al., 2014 (*Biomaterials*): Used iRGD-modified liposomes carrying a combination of paclitaxel and lonidamine in a glioblastoma model. Median survival increased from 21 days (untreated) to 35 days (standard liposomes) to 47 days (iRGD-modified liposomes) — a 34% survival extension compared to the best non-iRGD control.

Summary Evidence Table

---

Complete Dosing Guide for Research Protocols

iRGD is used in research contexts as a co-injection adjuvant. The dosing information below reflects experimental protocols from published literature and is intended strictly for preclinical research purposes.

Reconstitution Notes

iRGD lyophilized powder should be reconstituted in sterile water or phosphate-buffered saline (PBS, pH 7.4) to a stock concentration of 1 mg/mL. Vortex gently until fully dissolved. Do not heat. Working aliquots can be stored at -20°C for up to 3 months; avoid repeated freeze-thaw cycles. The disulfide bond is stable in PBS but will be destroyed by reducing agents — never add DTT or BME to iRGD solutions.

Preclinical Research Protocol (Mouse Models)

Critical timing note: The co-injection (simultaneous administration) protocol is used in most published research. Some studies have tested pre-administration of iRGD (5-15 minutes before drug) with comparable results, but sequential dosing where drug is given first and iRGD second does not replicate the penetration enhancement. The mechanistic rationale is that iRGD needs to open the transport pathway while the drug is still present in tumor vasculature.

Scaling to Larger Animal Models

Rat models typically use 50-100 μg per animal based on body surface area scaling from mouse doses. Primate and human-equivalent dosing has not been established in clinical trials as of the current evidence base, though Phase I clinical investigation has been initiated (see Future Directions section).

Key Variables That Affect Efficacy

Tumor αvβ3/NRP-1 expression level: iRGD works best in tumors that overexpress both αvβ3 integrins and NRP-1. Tumor types with low expression of either target show reduced penetration enhancement. Checking target expression via immunohistochemistry before designing an iRGD-based protocol is recommended.

Tumor protease activity: The CendR activation step requires protease activity in the tumor microenvironment. Tumors with high protease activity (many carcinomas, glioblastoma) show stronger iRGD effects than tumors with lower protease activity.

Co-agent size: iRGD enhances penetration of compounds ranging from small molecules (~500 Da) to large nanoparticles (~100 nm). Very large particles (>200 nm) may show reduced benefit because macropinosome size limits what can be transported.

---

Stacking Strategies: How Researchers Combine iRGD

Because iRGD works as a penetration enhancer rather than a direct therapeutic, every iRGD protocol is technically a stack. Here are the most studied and most promising combinations.

Stack 1: iRGD + Conventional Chemotherapy

This is the most established combination. The rationale is simple: most chemotherapy drugs fail in solid tumors not because they're ineffective against cancer cells, but because they never reach enough of those cells at adequate concentrations.

Protocol:

Best-studied combinations:

The rationale for using iRGD with nab-paclitaxel (abraxane) is particularly strong: abraxane was specifically developed to improve paclitaxel tumor penetration via albumin-binding mechanisms, and iRGD's CendR pathway appears to work synergistically with albumin-based transport, not competitively.

Stack 2: iRGD + Targeted Antibody Therapy

Monoclonal antibodies are large molecules that distribute poorly in solid tumors even when they target tumor-specific antigens. iRGD's ability to enhance antibody penetration opens the possibility of achieving equivalent therapeutic effect at lower antibody doses — with significant implications for cost and toxicity.

Protocol:

Key combinations in research:

The immunotherapy combination is particularly exciting. Checkpoint inhibitors like anti-PD-1 antibodies work by reinvigorating T cells to attack tumors, but T cell infiltration into tumor parenchyma is often limited by the same barrier that limits drug penetration. Early preclinical data suggest iRGD co-injection may increase immune cell infiltration alongside antibody penetration.

Stack 3: iRGD + Nanoparticle Drug Delivery Systems

Nanoparticle-based drug delivery was designed to exploit the EPR (Enhanced Permeability and Retention) effect — the tendency of macromolecules to accumulate in tumor tissue due to leaky vasculature. But EPR-based delivery is notoriously unreliable in humans, and nanoparticles that enter tumors typically remain clustered near blood vessels.

iRGD addresses both problems: it increases total tumor nanoparticle accumulation AND improves intratumoral distribution.

Protocol:

Nanoparticle types studied with iRGD:

---

Safety Deep Dive

iRGD's safety profile is an important consideration, though the research context is always co-administration rather than standalone treatment.

Common Observations in Preclinical Studies

Systemic toxicity: The most consistent finding across iRGD studies is the *absence* of increased systemic toxicity when iRGD is added to existing treatment regimens. The original *Science* paper specifically measured drug levels in heart (doxorubicin cardiotoxicity target), liver, and kidney when iRGD was co-administered and found no significant increases compared to drug alone. This selective tumor enhancement without systemic amplification is the most critical safety feature of iRGD.

Hemodynamic effects: At standard experimental doses in mice, iRGD does not cause observable hemodynamic changes. NRP-1 is involved in VEGF signaling and vascular tone regulation, but the doses used in iRGD research (10-20 μg/mouse) appear insufficient to cause systemic vascular disruption.

Injection site reactions: No significant injection site reactions have been reported in published iRGD literature at standard experimental doses.

Theoretical and Rare Risks

Off-target penetration enhancement: While the selectivity data is reassuring, it's based on the differential expression of αvβ3/αvβ5 and NRP-1 between tumor and normal vasculature. In conditions where normal tissues upregulate these receptors (wound healing, inflammation, angiogenesis), there is theoretical potential for off-target drug delivery enhancement. Researchers should be cautious about iRGD use in animal models with significant concurrent inflammatory conditions.

Immunogenicity: As a foreign cyclic peptide, iRGD could theoretically trigger immune responses with repeated administration. Published chronic administration studies (3x/week for several weeks) have not reported significant immune reactions, but this has not been systematically characterized across diverse genetic backgrounds.

Interaction with anti-angiogenic therapies: Because iRGD uses αvβ3 and NRP-1 — both VEGF pathway components — its combination with anti-angiogenic drugs (bevacizumab, sunitinib) requires careful consideration. Anti-angiogenic drugs may reduce tumor vessel αvβ3 expression, potentially blunting iRGD's first binding step. Conversely, vascular normalization by anti-angiogenics might improve iRGD access to remaining vessels. The interaction is unpredictable and should be characterized empirically.

NRP-1 modulation concerns: NRP-1 serves as a co-receptor not just for VEGF but also for semaphorins, which regulate axonal guidance and immune cell migration. Sustained NRP-1 activation or competition could theoretically affect neurological or immunological functions. No such effects have been reported in published iRGD studies, but systematic neurological assessment hasn't been a standard endpoint.

Contraindications for Research Use

---

iRGD Compared to Alternatives

Several other strategies exist for improving tumor drug penetration. How does iRGD compare?

Chlorotoxin — while an interesting comparison for GBM targeting — is limited to a narrow tumor type, whereas iRGD's mechanism works across a far broader range of solid tumors expressing αvβ3 and NRP-1.

The comparison with PEGPH20 (pegylated hyaluronidase) is instructive. PEGPH20 degrades hyaluronan in tumor stroma to improve drug penetration — a logical approach that showed promise in preclinical models but failed in Phase III trials for pancreatic cancer partly due to thromboembolic toxicity. iRGD achieves similar penetration enhancement without destroying tumor stroma, potentially preserving the structural environment that some immunotherapy approaches need intact.

---

What's Coming Next: Active Research and Unanswered Questions

Clinical Translation

The most significant development in iRGD research is the move toward human trials. A Phase I clinical trial (NCT02683850) investigated iRGD combined with nab-paclitaxel in patients with advanced solid tumors. This was the first human study of the co-injection principle. Initial safety data from this trial has been reported as acceptable, though full efficacy data from Phase II expansion is still being analyzed.

The fundamental challenge for clinical translation is predictive biomarker development. Not all tumors respond equally to iRGD — target expression (αvβ3, NRP-1) and tumor protease activity vary significantly between patients and tumor types. A companion diagnostic that predicts iRGD responsiveness would be enormously valuable for patient selection.

iRGD in Immunotherapy Combinations

Perhaps the most exciting emerging application is combining iRGD with immune checkpoint inhibitors. The rationale: anti-PD-1/PD-L1 antibodies work by releasing the brakes on T cells, but T cell infiltration into tumor parenchyma is often the rate-limiting step. If iRGD can drive checkpoint inhibitors deeper into tumors while simultaneously facilitating T cell infiltration, the combination might rescue some of the 60-70% of patients who don't respond to current checkpoint inhibitor monotherapy.

A 2020 study by Pang et al. in *Journal for ImmunoTherapy of Cancer* showed that iRGD co-injection with anti-PD-1 antibody in poorly immunogenic 4T1 breast tumors increased tumor T cell density by 2.3-fold and improved response rates significantly compared to anti-PD-1 alone. Whether this translates to clinical benefit is the central unanswered question driving current trials.

iRGD-Drug Conjugates

While the co-injection paradigm is elegant, pharmaceutical development often favors defined single-molecule entities. Several groups are developing iRGD-drug conjugates where therapeutic payloads are chemically attached to the iRGD scaffold. This approach allows precise pharmacokinetic characterization and avoids the variability inherent in co-injection timing.

The challenge is that conjugation to the iRGD ring structure can interfere with integrin binding or CendR exposure. Several linker strategies have been developed to attach payloads at positions that don't compromise the two-step mechanism, but this remains an active engineering challenge.

CAR-T Cell Delivery

CAR-T cell therapy has transformed blood cancer treatment but largely failed in solid tumors because CAR-T cells cannot infiltrate the tumor microenvironment effectively. A 2022 preclinical study demonstrated that iRGD pre-treatment of tumors (delivered before CAR-T infusion, rather than co-injected) increased CAR-T cell infiltration into solid tumors. If this approach is validated, it would represent a completely new application: using iRGD not to deliver drugs but to open tumors to cellular therapies.

Specific Questions That Remain Open

Duration of the transcytosis window: Most protocols assume iRGD must be co-injected simultaneously with the therapeutic. The exact duration of the NRP-1-mediated transcytosis window after iRGD binding is not precisely characterized. Defining this window would allow optimization of dosing timing.

Optimal dosing in larger animals and humans: The 10 μg/mouse dose that dominates the literature doesn't straightforwardly scale to humans. Body surface area scaling, receptor saturation kinetics, and tumor size all complicate dose translation. Phase I PK/PD data will be essential.

Effect on tumor immune microenvironment over time: Chronic iRGD administration may alter the tumor immune microenvironment in ways that are beneficial (increased immune infiltration) or potentially detrimental (altered stromal architecture). Long-term characterization is needed.

Resistance mechanisms: Do tumors downregulate αvβ3, NRP-1, or relevant proteases in response to repeated iRGD exposure? Acquired resistance to tumor-targeting peptides is rarely studied but could limit chronic treatment protocols.

---

Key Takeaways

---

🔬 Explore our peptide database — Browse 500+ research peptide profiles with mechanisms, dosing, and evidence.

🛒 Ready to buy? — Browse our verified vendor shop for third-party tested peptides.

🤖 Have questions? — Ask PeptideAI for personalized peptide guidance.

📚 Want more guides? — Browse all research articles covering peptide science and buying guides.

---

Related Articles on BuyPeptidesOnline.com